Coronary/Structural Heart

GUIDE-HF Study Data Show Abbott’s CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure

– The GUIDE-HF study examined the potential impact of Abbott’s CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device – Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and […]

Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting

Firibastat is as efficient as the current standard of care (ramipril) in preventing the degradation of the left ventricular ejection fraction (primary endpoint) after myocardial infarction in full study population Firibastat demonstrated better efficacy compared to ramipril in severe patients with low ejection fraction Firibastat improved blood pressure profile in […]

CARMAT Announces a New Commercial Implant of Its Aeson® Artificial Heart at University Medical Center Schleswig-holstein in Kiel, Germany

PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its Aeson® bioprosthetic artificial heart in a commercial setting. This new […]

Baylis Medical Announces First Clinical Case Using the VersaCross® Large Access Solution in Canada

TORONTO, Aug. 25, 2021 /PRNewswire/ – Baylis Medical announced today the first clinical use of the VersaCross® Large Access Solution in Canada, to perform a Left Atrial Appendage Closure (LAAC) procedure. The new solution includes the world’s first 3-in-1 radiofrequency (RF) wire paired with a seamless shapeable dilator designed to optimize tissue dilation […]

CARMAT Announces the Second Center Implanting Its Total Artificial Heart in the United States

The implant was performed at UofL Health – Jewish Hospital by University of Louisville physicians within the framework of the U.S. Early Feasibility Study PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by […]

Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

Evolut™ FX TAVR System Adds Innovative Features to Enhance Ease-of-Use and Predictable Valve Deployment DUBLIN, Aug. 24, 2021 /PRNewswire/ — Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut™ FX TAVR system. […]

Preliminary Dan-NICAD II results to be presented at ESC

Malmö, Sweden, August 23, 2021 Preliminary Dan-NICAD II results to be presented at ESC Acarix AB (publ) today announced that the preliminary results of the Dan-NICAD II study will be presented at the ESC congress on 27AUG2021. The Dan-NICAD II trial was initiated in January 2018 to assess non-invasive methods in patients referred to CCTA (Coronary Computed Tomography […]

Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of Cardiology

VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that data adding to the growing body […]

Lexicon’s Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials

Rapid benefit of sotagliflozin supported by data from the SOLOIST and SCORED trials presented at ESC Congress 2021 – The Digital Experience, including: 33% absolute risk reduction in the composite cardiovascular endpoint in type 2 diabetes patients with acute decompensated heart failure (HF), with consistent results among patients with preserved […]

Cardiac Dimensions® Announces Launch of Its Optimized U.S. Pivotal Trial – The EMPOWER Trial

International Study to Evaluate Innovative Minimally Invasive Treatment for Heart Failure With Early-Stage Functional Mitral Regurgitation   KIRKLAND, Wash., Aug. 20, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the launch of the U.S. […]